Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2060204
Abstract: ABSTRACT Background Tocilizumab is a recombinant humanized monoclonal immunoglobulin G1 antibody against the interleukin-6 receptor (IL-6 R). MSB11456 is a proposed tocilizumab biosimilar. Objectives To assess the pharmacokinetic and pharmacodynamic similarity of MSB11456 to both… read more here.
Keywords: approved tocilizumab; proposed tocilizumab; msb11456 licensed; licensed approved ... See more keywords